MersV1, PubMed, Curation, bibRecord, 000120

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.

Identifieur interne : 000120 ( PubMed/Curation ); précédent : 000119; suivant : 000121

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.

Source :

Life sciences [ 1879-0631 ] ; 2020.

RBID : pubmed:32222463

Abstract

A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began spreading in December 2019 in Wuhan City, China causing pneumonia called COVID-19. The spread of SARS-CoV-2 has been faster than any other coronaviruses that have succeeded in crossing the animal-human barrier. There is concern that this new virus will spread around the world as did the previous two HCoVs-Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)-each of which caused approximately 800 deaths in the years 2002 and 2012, respectively. Thus far, 11,268 deaths have been reported from the 258,842 confirmed infections in 168 countries.

DOI: 10.1016/j.lfs.2020.117592
PubMed: 32222463

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000120

Links to Exploration step

pubmed:32222463

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.</title>
<author><name sortKey="Elfiky, Abdo A" sort="Elfiky, Abdo A" uniqKey="Elfiky A" first="Abdo A" last="Elfiky">Abdo A. Elfiky</name>
<affiliation wicri:level="1"><nlm:affiliation>Biophysics Department, Faculty of Sciences, Cairo University, Giza, Egypt. Electronic address: abdo@sci.cu.edu.eg.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Biophysics Department, Faculty of Sciences, Cairo University, Giza</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32222463</idno>
<idno type="pmid">32222463</idno>
<idno type="doi">10.1016/j.lfs.2020.117592</idno>
<idno type="wicri:Area/PubMed/Corpus">000120</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000120</idno>
<idno type="wicri:Area/PubMed/Curation">000120</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000120</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.</title>
<author><name sortKey="Elfiky, Abdo A" sort="Elfiky, Abdo A" uniqKey="Elfiky A" first="Abdo A" last="Elfiky">Abdo A. Elfiky</name>
<affiliation wicri:level="1"><nlm:affiliation>Biophysics Department, Faculty of Sciences, Cairo University, Giza, Egypt. Electronic address: abdo@sci.cu.edu.eg.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Biophysics Department, Faculty of Sciences, Cairo University, Giza</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Life sciences</title>
<idno type="eISSN">1879-0631</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began spreading in December 2019 in Wuhan City, China causing pneumonia called COVID-19. The spread of SARS-CoV-2 has been faster than any other coronaviruses that have succeeded in crossing the animal-human barrier. There is concern that this new virus will spread around the world as did the previous two HCoVs-Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)-each of which caused approximately 800 deaths in the years 2002 and 2012, respectively. Thus far, 11,268 deaths have been reported from the 258,842 confirmed infections in 168 countries.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32222463</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0631</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Mar</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>Life sciences</Title>
<ISOAbbreviation>Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.</ArticleTitle>
<Pagination><MedlinePgn>117592</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0024-3205(20)30340-4</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lfs.2020.117592</ELocationID>
<Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began spreading in December 2019 in Wuhan City, China causing pneumonia called COVID-19. The spread of SARS-CoV-2 has been faster than any other coronaviruses that have succeeded in crossing the animal-human barrier. There is concern that this new virus will spread around the world as did the previous two HCoVs-Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)-each of which caused approximately 800 deaths in the years 2002 and 2012, respectively. Thus far, 11,268 deaths have been reported from the 258,842 confirmed infections in 168 countries.</AbstractText>
<AbstractText Label="MAIN METHODS" NlmCategory="METHODS">In this study, the RNA-dependent RNA polymerase (RdRp) of the newly emerged coronavirus is modeled, validated, and then targeted using different anti-polymerase drugs currently on the market that have been approved for use against various viruses.</AbstractText>
<AbstractText Label="KEY FINDINGS" NlmCategory="RESULTS">The results suggest the effectiveness of Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir as potent drugs against SARS-CoV-2 since they tightly bind to its RdRp. In addition, the results suggest guanosine derivative (IDX-184), Setrobuvir, and YAK as top seeds for antiviral treatments with high potential to fight the SARS-CoV-2 strain specifically.</AbstractText>
<AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">The availability of FDA-approved anti-RdRp drugs can help treat patients and reduce the danger of the mysterious new viral infection COVID-19. The drugs mentioned above can tightly bind to the RdRp of the SARS-CoV-2 strain and thus may be used to treat the disease. No toxicity measurements are required for these drugs since they were previously tested prior to their approval by the FDA.</AbstractText>
<CopyrightInformation>Copyright © 2020. Published by Elsevier Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elfiky</LastName>
<ForeName>Abdo A</ForeName>
<Initials>AA</Initials>
<AffiliationInfo><Affiliation>Biophysics Department, Faculty of Sciences, Cairo University, Giza, Egypt. Electronic address: abdo@sci.cu.edu.eg.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>03</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Life Sci</MedlineTA>
<NlmUniqueID>0375521</NlmUniqueID>
<ISSNLinking>0024-3205</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Drug repurposing</Keyword>
<Keyword MajorTopicYN="N">Molecular docking</Keyword>
<Keyword MajorTopicYN="N">RdRp</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">Structural bioinformatics</Keyword>
</KeywordList>
<CoiStatement>Declaration of competing interest The author declares that there is no competing interest in this work.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>02</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>03</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>03</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>3</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>3</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32222463</ArticleId>
<ArticleId IdType="pii">S0024-3205(20)30340-4</ArticleId>
<ArticleId IdType="doi">10.1016/j.lfs.2020.117592</ArticleId>
<ArticleId IdType="pmc">PMC7102646</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Med Virol. 2018 Jan;90(1):13-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28922464</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2012 Aug 24;425(2):485-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22877750</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Comput Chem. 2009 Dec;30(16):2785-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19399780</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 2017 Jun;89(6):1040-1047</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27864902</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Comput Chem. 2010 Jan 30;31(2):455-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19499576</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Opin Struct Biol. 1998 Dec;8(6):704-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9914251</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Med Chem. 2019;15(2):130-137</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30324891</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 2016 Dec;88(12):2044-2051</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27604059</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Protein Sci. 2018 Jan;27(1):293-315</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29067766</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 1996 May 23;381(6580):272</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8692262</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Med Chem Res. 2016;25(5):1005-1008</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32214769</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Microbiol Rev. 2015 Apr;28(2):465-522</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25810418</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Commun. 2019 May 28;10(1):2342</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31138817</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2014 Nov;88(21):12511-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25142582</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Mol Biol. 1996 Nov 22;264(1):121-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8950272</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>SAR QSAR Environ Res. 2018 May;29(5):409-418</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29652194</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Mol Model. 2007 Dec;13(12):1173-213</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17828561</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biomol NMR. 1996 Dec;8(4):477-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9008363</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Int J Infect Dis. 2020 Feb;91:264-266</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31953166</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Protein J. 2013 Jan;32(1):75-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23322006</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000120 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000120 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:32222463
   |texte=   Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:32222463" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki